Amarin Corporation plc (AMRN) Insider Trading Activity

NASDAQ$13.93
Market Cap
$288.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
434 of 870
Rank in Industry
257 of 505

AMRN Insider Trading Activity

AMRN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Insider Activity of Amarin Corporation plc

Over the last 12 months, insiders at Amarin Corporation plc have bought $0 and sold $0 worth of Amarin Corporation plc stock.

On average, over the past 5 years, insiders at Amarin Corporation plc have bought $140,542 and sold $328,602 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 160,000 shares for transaction amount of $102,400 was made by Berg Aaron (President and CEO) on 2024‑08‑02.

List of Insider Buy and Sell Transactions, Amarin Corporation plc

2024-08-02PurchaseBerg AaronPresident and CEO
160,000
0.0389%
$0.64
$102,400
-10.16%
2024-01-22PurchaseHolt PatrickPresident and CEO
14,426
0.0033%
$1.09
$15,724
-39.30%
2023-12-12SaleKetchum Steven BChief Scientific Officer
34,131
0.0084%
$0.79
$26,963
-0.54%
2023-08-16PurchaseHolt PatrickPresident and CEO
300,000
0.0723%
$1.04
$312,315
-18.77%
2022-06-13PurchaseWOLD OLSEN PER
55,000
0.0137%
$1.69
$92,730
-21.76%
2021-12-15PurchaseZakrzewski Joseph Sdirector
2,000
0.0005%
$3.15
$6,310
-52.31%
2021-12-14PurchaseZakrzewski Joseph Sdirector
10,000
0.0025%
$3.27
$32,689
-52.00%
2021-08-12SaleKalb Michael WayneSVP and CFO
120,000
0.0282%
$5.25
$630,240
-41.05%
2021-06-04PurchaseSTACK DAVID Mdirector
10,000
0.0026%
$4.54
$45,350
-17.42%
2021-06-03PurchaseSTACK DAVID Mdirector
5,000
0.0013%
$4.62
$23,115
-19.61%
2021-02-01SaleKetchum Steven BChief Scientific Officer
435,456
0.11%
$8.06
$3.51M
-39.85%
2021-01-27SaleKetchum Steven BChief Scientific Officer
843,258
0.2332%
$8.01
$6.76M
-33.52%
2020-11-30PurchaseSTACK DAVID Mdirector
50,000
0.0125%
$4.86
$243,035
+1.61%
2020-11-11SaleTHERO JOHN FPresident and CEO
827,130
0.2094%
$4.07
$3.36M
+22.63%
2020-11-10SaleTHERO JOHN FPresident and CEO
307,680
0.0792%
$4.13
$1.27M
+22.63%
2020-03-04SaleTHERO JOHN FPresident and CEO
400,000
0.1106%
$15.99
$6.4M
-58.77%
2020-01-03SaleZakrzewski Joseph Sdirector
600,000
0.0965%
$12.17
$7.3M
-67.88%
2019-12-16SaleBerg AaronCHIEF COMMERCIAL OFFICER
86,506
0.02%
$19.03
$1.65M
-70.15%
2019-12-16SaleZakrzewski Joseph Sdirector
200,000
0.0424%
$17.42
$3.48M
-70.15%
2019-12-16SaleKalb Michael WayneSVP and CFO
50,000
0.0142%
$23.36
$1.17M
-70.15%
Total: 191

Insider Historical Profitability

13.95%
SOFINNOVA VENTURE PARTNERS VII L P10 percent owner
8513388
41.1617%
$118.59M07
HEALY JAMESdirector
5513388
26.6569%
$76.8M04
THERO JOHN FPresident and CEO
2739000
13.2429%
$38.15M69
+65.82%
Abingworth LLP10 percent owner
1599168
7.7319%
$22.28M011
Berg AaronPresident and CEO
805380
3.894%
$11.22M14
<0.0001%
Ketchum Steven BChief Scientific Officer
566100
2.7371%
$7.89M021
Holt PatrickPresident and CEO
314426
1.5202%
$4.38M20
<0.0001%
Kalb Michael WayneSVP and CFO
205010
0.9912%
$2.86M08
Zakrzewski Joseph Sdirector
196547
0.9503%
$2.74M316
<0.0001%
WOLD OLSEN PER
149000
0.7204%
$2.08M10
<0.0001%
STACK DAVID Mdirector
40000
0.1934%
$557,200.0034
<0.0001%
Kennedy Joseph TGeneral Counsel
31260
0.1511%
$435,451.80027
VAN HEEK G JANdirector
14168
0.0685%
$197,360.2403
Farrell Michael JamesController
6037
0.0292%
$84,095.4110
+140.48%
ORBIMED ADVISORS LLCdirector
5700
0.0276%
$79,401.00021
GORDON CARL Ldirector
5700
0.0276%
$79,401.00021
SEDLACK STUART DSenior Vice President
0
0%
$001
Ekman Larsdirector
0
0%
$015
<0.0001%
Ahlholm Frederick WVice President Finance
0
0%
$002
Soni PareshSVP and Head of Development
0
0%
$002
Peterson Kristinedirector
0
0%
$001
Huff PaulChief Commercial Officer
0
0%
$006

Historical Insider Profitability vs. Competitors

$5,911,307
70
-1.38%
$257.15M
$60,836,085
69
0.45%
$296.66M
$17,468,215
46
18.85%
$303.9M
$8,587,568
37
47.91%
$291.43M
$64,573,910
36
-14.02%
$303.72M
$63,049,419
31
2.87%
$302.01M
$41,505,594
29
21.51%
$282.1M
$79,019,806
27
7.24%
$271.28M
Amarin Corporation plc
(AMRN)
$1,447,973
17
13.95%
$288.11M
$104,137,421
15
21.28%
$300.28M
$135,842,093
15
16.77%
$260.54M
$10,399,379
13
13.60%
$261.88M
$6,385,840
12
0.69%
$295.34M
$112,952,085
11
-19.19%
$291.46M
$6,847,110
9
5.96%
$265.31M
$13,258,734
9
18.72%
$276.91M
$91,549,696
8
-6.55%
$275.33M
$747,947
6
10.18%
$279.31M
$37,067
3
-89.81%
$302.03M

AMRN Institutional Investors: Active Positions

Increased Positions37+35.24%957,015+23.44%
Decreased Positions37-35.24%441,129-10.8%
New Positions10New83,485New
Sold Out Positions19Sold Out137,407Sold Out
Total Postitions1050%5M+12.63%

AMRN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Sarissa Capital Management Lp$17,047.000.3%1.24M00%2025-09-30
Kynam Capital Management, Lp$7,904.000.14%576,11100%2025-09-30
Acadian Asset Management Llc$6,264.000.11%456,580+215,532+89.42%2025-09-30
Morgan Stanley$3,700.000.07%269,663+106,697+65.47%2025-09-30
Eversept Partners, Lp$2,295.000.04%167,27600%2025-09-30
Millennium Management Llc$1,816.000.03%132,391+87,147+192.62%2025-09-30
Citadel Advisors Llc$1,678.000.03%122,291+76,835+169.03%2025-09-30
Scp Investment, Lp$1,372.000.02%100,000-25,000-20%2025-09-30
Bnp Paribas Financial Markets$1,199.000.02%87,366+11,425+15.04%2025-09-30
Susquehanna International Group, Llp$1,099.000.02%80,109+37,327+87.25%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.